These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 1956989)
1. Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response. Beinfeld MC; Garver DL Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(5):601-9. PubMed ID: 1956989 [TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin, dopamine and schizophrenia. Garver DL; Beinfeld MC; Yao JK Psychopharmacol Bull; 1990; 26(3):377-80. PubMed ID: 2274639 [TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid cholecystokinin, bombesin and somatostatin in schizophrenia and normals. Gerner RH; van Kammen DP; Ninan PT Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(1):73-82. PubMed ID: 2859635 [TBL] [Abstract][Full Text] [Related]
5. Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures. Peters J; Van Kammen DP; Gelernter J; Yao J; Shaw D Schizophr Res; 1990; 3(5-6):287-94. PubMed ID: 2178001 [TBL] [Abstract][Full Text] [Related]
6. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Garver DL; Bissette G; Yao JK; Nemeroff CB Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695 [TBL] [Abstract][Full Text] [Related]
7. Beta-endorphin, vasoactive intestinal peptide and cholecystokinin in peripheral blood mononuclear cells from healthy subjects and from drug-free and haloperidol-treated schizophrenic patients. Panza G; Monzani E; Sacerdote P; Penati G; Panerai AE Acta Psychiatr Scand; 1992 Mar; 85(3):207-10. PubMed ID: 1561892 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia. Forman SD; Bissette G; Yao J; Nemeroff CB; van Kammen DP Schizophr Res; 1994 Apr; 12(1):43-51. PubMed ID: 8018584 [TBL] [Abstract][Full Text] [Related]
9. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited. van Kammen DP; Peters J; Yao J; van Kammen WB; Neylan T; Shaw D; Linnoila M Arch Gen Psychiatry; 1990 Feb; 47(2):161-8. PubMed ID: 1689140 [TBL] [Abstract][Full Text] [Related]
10. Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. Bachus SE; Hyde TM; Herman MM; Egan MF; Kleinman JE J Psychiatr Res; 1997; 31(2):233-56. PubMed ID: 9278188 [TBL] [Abstract][Full Text] [Related]
12. CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships. van Kammen DP; Guidotti A; Kelley ME; Gurklis J; Guarneri P; Gilbertson MW; Yao JK; Peters J; Costa E Biol Psychiatry; 1993 Oct; 34(8):515-22. PubMed ID: 8274578 [TBL] [Abstract][Full Text] [Related]
13. Reduced cholecystokinin levels in cerebrospinal fluid of parkinsonian and schizophrenic patients. Effect of ceruletide in schizophrenia. Lotstra F; Verbanck PM; Gilles C; Mendlewicz J; Vanderhaeghen JJ Ann N Y Acad Sci; 1985; 448():507-17. PubMed ID: 3896098 [No Abstract] [Full Text] [Related]
14. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208 [TBL] [Abstract][Full Text] [Related]
15. ERPs in schizophrenia: effects of antipsychotic medication. Ford JM; White PM; Csernansky JG; Faustman WO; Roth WT; Pfefferbaum A Biol Psychiatry; 1994 Aug; 36(3):153-70. PubMed ID: 7948453 [TBL] [Abstract][Full Text] [Related]
16. Cholecystokinin, beta-endorphin and vasoactive intestinal peptide in peripheral blood mononuclear cells of drug-naive schizophrenic patients treated with haloperidol compared to healthy controls. Mauri MC; Rudelli R; Vanni S; Panza G; Sicaro A; Audisio D; Sacerdote P; Panerai AE Psychiatry Res; 1998 Mar; 78(1-2):45-50. PubMed ID: 9579701 [TBL] [Abstract][Full Text] [Related]
17. Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients. van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Condray R; Peters JL Neuropsychopharmacology; 1996 Apr; 14(4):275-83. PubMed ID: 8924195 [TBL] [Abstract][Full Text] [Related]
18. Lithium prevents adaptation of brain dopamine systems to haloperidol in schizophrenic patients. Sternberg DE; Bowers MB; Heninger GR; Charney DS Psychiatry Res; 1983 Oct; 10(2):79-86. PubMed ID: 6581492 [TBL] [Abstract][Full Text] [Related]
19. Haloperidol does not affect the level of serum-soluble interleukin-2 receptor in drug-free male schizophrenics. Kim CE; Kang DY; Ha KS; Jeong SH; Kim YS Biol Psychiatry; 1995 Dec; 38(12):843-5. PubMed ID: 8750045 [No Abstract] [Full Text] [Related]
20. Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial. Wilson WH Psychopharmacology (Berl); 1993; 111(3):359-66. PubMed ID: 7870975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]